Search Results

Here, we demonstrate using various fluorescence imaging approaches at the single cell level to measure

Dasatinib-induced ERK activation was completely abolished by exposure to the FDA-approved MEK inhibitor The results provide rationale for considering a combination(s) of FDA-approved SFK (dasatinib) and MEK

TMC Score of 3.2 Units in Valbenazine-Treated Patients- Company Plans to Submit Supplemental New Drug Application

(“Neurocrine Biosciences”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino With completion of the applicable waiting period under the HSR Act, under the terms of the License Agreement

In this newly created role, she will focus on the application of artificial intelligence (AI), machine

It captures our values and vision for the future, our culture, and our unique approach to science.

January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position

Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous

. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical Co., Ltd.

ASCI, the Association of American Physicians (AAP), and the American Physician-Scientists Association (APSA ) on April 8, 2022

For example, chemotherapy, a powerful standard approach to kill fast-growing cancer cells, has the drawback Modern drug development approaches include a range of techniques leveraging structural biology, immunology

This prompted us to investigate the specificity of FAB6695 and scrutinize the apparent ACKR1 expression

This award recognizes the combination of Steyaert’s fundamental research and his ability to apply the

which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately

As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx.

ACKR3 has been described as an atypical "biased" receptor because it does not appear to signal through The development of more selective ACKR3 ligands should allow us to better appreciate the unique roles

Experimental approach: We used a bio-guided screening assay to identify novel MQs and placed them phylogenetically

Therefore, S1R ligands possess a variety of potential clinical applications with a great interest in

To overcome this potential uncertainty, we used a homologous recombination-based knockin (KI) approach the endogenous mouse promoter and hence occurs in all biologically relevant cells and tissues and at appropriate

Senior Vice President, Head of Research, Peter McNamara, PhD, to Chief Scientific Officer as well as the appointments

In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs. high number of GPCR targeted drugs, only a small portion (∼110) of the human GPCRome (consisting of approximately

April 2022 "By Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate

May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics, Inc., a venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced four appointments to its Scientific Advisory

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel

April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform "April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund "CHESTERBROOK, Pa., April 18, 2022 - Trevena